EVALUATION OF MINIMAL RESIDUAL DISEASE IN HIGH-RISK CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA USING AN IMMUNOLOGICAL APPROACH DURING COMPLETE REMISSION

被引:0
|
作者
CONSOLINI, R
SCAMARDELLA, F
LEGITIMO, A
PUTTI, C
GRANCHI, D
PAOLUCCI, P
LIPPI, A
GUAZZELLI, C
ACQUAVIVA, A
ROSANDA, C
BASSO, G
MACCHIA, P
机构
[1] UNIV PADUA, DIPARTIMENTO PEDIAT, I-35100 PADUA, ITALY
[2] UNIV BOLOGNA, PEDIAT CLIN 3, I-40126 BOLOGNA, ITALY
[3] UNIV FLORENCE, PEDIAT CLIN, I-50121 FLORENCE, ITALY
[4] UNIV SIENA, IST CLIN PEDIAT, I-53100 SIENA, ITALY
[5] IST GIOVANNA GASLINI, GENOA, ITALY
关键词
MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; COMPLETE REMISSION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Sensitive methods for detecting residual disease may complement conventional morphology while monitoring the response to treatment in leukemia patients. Methods. We studied minimal residual disease (MRD) by selecting via a colony assay a peripheral blood (PB) cell population enriched in putative malignant cells and detecting occult leukemic cells by double immunologic analysis performed on colonyforming cells (CFC). Using this combined technique we assayed the PB of high risk children with acute lymphoblastic leukemia (ALL) in order to demonstrate possible differences in <<the residual tumor cell burden>> among leukemia patients and to correlate these with a 3-year clinical follow-up. Results. In all 22 patients positive results were obtained for up to 18 months following induction chemotherapy at times of apparent hematologic remission. Common ALL (cALL) patients exhibited a mean of 9.6% cAlla+ cells (range: 2% to 30%), whereas cALL antigen (cALLA) and cALLA/Tdt or CDla/Tdt combination were never found in the colonies derived from healthy individuals. Six out of 22 cALL patients expressed a mean of 16.5% cALLA+/Tdt+ CFC (range: 2% to 35%). Five TALL children presented a mean of 24% CD1a/Tdt+ cells (range: 8% to 44%). Extensive follow-up indicates a correlation between the percentage of CFC Tdt+/lymphoid marker+ cells (more than 10%) and subsequent clinical relapse. In one patient relapse occurred after 16 months with a dramatic increase in the number of leukemic cells. In contrast, the decline in malignant cells, observed in two cases, predicted a favourable course. Five patients tested before autologous bone marrow transplantation (ABMT) presented high number of positive cells and relapsed at various times. Conclusions. We conclude that this approach to the study of MRD could be valuable in monitoring the efficacy of chemotherapy, as well in evaluating the quality of purged marrow.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 50 条
  • [21] SUPERIOR TREATMENT RESULTS IN FEMALES WITH HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA IN CHILDHOOD
    LANNING, M
    GARWICZ, S
    HERTZ, H
    JONMUNDSSON, G
    KREUGER, A
    LIE, SO
    MOE, PJ
    SALMI, TT
    SCHRODER, H
    SIIMES, MA
    WESENBERG, F
    YSSING, M
    AHSTROM, L
    GUSTAFSSON, G
    ACTA PAEDIATRICA, 1992, 81 (01) : 66 - 68
  • [22] IMMUNOLOGICAL MONITORING OF RESIDUAL DISEASE IN TREATED THYMIC ACUTE LYMPHOBLASTIC-LEUKEMIA
    BRADSTOCK, KF
    JANOSSY, G
    TIDMAN, N
    PAPAGEORGIOU, ES
    PRENTICE, HG
    WILLOUGHBY, M
    HOFFBRAND, AV
    LEUKEMIA RESEARCH, 1981, 5 (4-5) : 301 - 309
  • [23] Prospective evaluation of minimal residual disease (MRD) in high-risk childhood acute lymphoblastic leukemia in the ongoing trial ALL-BFM 2000
    Schrauder, A
    Flohr, T
    Zimmermann, M
    Koch, D
    Stanulla, M
    Lauten, M
    Welte, K
    Bartram, C
    Schrappe, M
    BONE MARROW TRANSPLANTATION, 2002, 30 : S60 - S60
  • [24] Minimal residual disease monitoring in childhood acute lymphoblastic leukemia
    Campana, Dario
    CURRENT OPINION IN HEMATOLOGY, 2012, 19 (04) : 313 - 318
  • [25] High-Risk Childhood Acute Lymphoblastic Leukemia
    Bhojwani, Deepa
    Howard, Scott C.
    Pui, Ching-Hon
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S222 - S230
  • [26] Analysis of Molecular Minimal Residual Disease in Patients with Acute Leukemia during Complete Remission
    Zhang, Yang
    Wang, Fang
    Chen, Xue
    Zhang, Yu
    Wang, Mingyu
    Liu, Hong
    Lu Peihua
    Liu, Hongxing
    BLOOD, 2018, 132
  • [27] THE USE OF THE POLYMERASE CHAIN-REACTION TO DETECT MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA
    STEWARD, CG
    GOULDEN, NJ
    POTTER, MN
    OAKHILL, A
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (08) : 1192 - 1198
  • [28] ADULT VISCERAL MEDITERRANEAN LEISHMANIASIS DURING COMPLETE REMISSION OF ACUTE LYMPHOBLASTIC-LEUKEMIA
    GASTAUT, JA
    BLANC, AP
    IMBERT, C
    SEBAHOUN, G
    CARCASSONNE, Y
    NOUVELLE PRESSE MEDICALE, 1981, 10 (16): : 1332 - 1332
  • [29] DEFINITION OF THE HIGH-RISK ACUTE LYMPHOBLASTIC-LEUKEMIA PATIENT BY IMMUNOLOGICAL PHENOTYPING WITH MONOCLONAL-ANTIBODIES
    ZIPF, TF
    FOX, RI
    DILLEY, J
    LEVY, R
    CANCER RESEARCH, 1981, 41 (11) : 4786 - 4789
  • [30] AREA DEPRIVATION AND MINIMAL RESIDUAL DISEASE IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
    Muniz, Josh
    Getz, Kelly
    Miller, Tamara
    Lupo, Philip
    Aplenc, Richard
    Rabin, Karen
    Schraw, Jeremy
    Gramatges, Maria Monica
    PEDIATRIC BLOOD & CANCER, 2022, 69